Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acid Ceramidase | 7 | 2020 | 85 | 1.870 |
Why?
|
| Prostatic Neoplasms | 8 | 2013 | 778 | 1.480 |
Why?
|
| Sphingolipids | 9 | 2019 | 337 | 1.240 |
Why?
|
| Antineoplastic Agents | 10 | 2013 | 1070 | 1.070 |
Why?
|
| Galactosylgalactosylglucosylceramidase | 8 | 2008 | 39 | 1.070 |
Why?
|
| Ceramides | 11 | 2019 | 578 | 0.920 |
Why?
|
| Hematologic Tests | 1 | 2019 | 24 | 0.710 |
Why?
|
| Neoplasms | 4 | 2019 | 1660 | 0.690 |
Why?
|
| Enzyme Inhibitors | 8 | 2014 | 659 | 0.670 |
Why?
|
| Inpatients | 1 | 2019 | 208 | 0.620 |
Why?
|
| Sphingosine | 6 | 2019 | 315 | 0.610 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2013 | 756 | 0.600 |
Why?
|
| Capsid Proteins | 2 | 2006 | 27 | 0.580 |
Why?
|
| Lysophospholipids | 5 | 2019 | 209 | 0.560 |
Why?
|
| Cell Line, Tumor | 13 | 2019 | 1849 | 0.550 |
Why?
|
| Up-Regulation | 4 | 2012 | 682 | 0.500 |
Why?
|
| Apoptosis | 5 | 2013 | 1640 | 0.500 |
Why?
|
| Head and Neck Neoplasms | 4 | 2019 | 561 | 0.460 |
Why?
|
| Hospitalization | 1 | 2019 | 977 | 0.460 |
Why?
|
| Cytoplasm | 1 | 2013 | 155 | 0.450 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 107 | 0.440 |
Why?
|
| Propanolamines | 5 | 2014 | 70 | 0.440 |
Why?
|
| Cell Nucleus | 1 | 2013 | 305 | 0.430 |
Why?
|
| Cathepsin B | 1 | 2012 | 33 | 0.420 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2012 | 65 | 0.420 |
Why?
|
| Cell Death | 1 | 2012 | 329 | 0.410 |
Why?
|
| Mice, Nude | 7 | 2019 | 294 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 331 | 0.400 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 369 | 0.400 |
Why?
|
| Genetic Therapy | 3 | 2008 | 291 | 0.400 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 475 | 0.380 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2013 | 332 | 0.350 |
Why?
|
| Amides | 4 | 2014 | 86 | 0.350 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 332 | 0.340 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2008 | 35 | 0.330 |
Why?
|
| Mitochondria | 1 | 2012 | 643 | 0.310 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2012 | 304 | 0.270 |
Why?
|
| Animals | 13 | 2020 | 20877 | 0.260 |
Why?
|
| Myristates | 3 | 2008 | 21 | 0.240 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2019 | 624 | 0.240 |
Why?
|
| Mice | 8 | 2020 | 8472 | 0.230 |
Why?
|
| Humans | 23 | 2020 | 68525 | 0.210 |
Why?
|
| Arthritis, Experimental | 1 | 2020 | 38 | 0.190 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 77 | 0.180 |
Why?
|
| Antigen Presentation | 1 | 2020 | 76 | 0.180 |
Why?
|
| Male | 11 | 2019 | 37281 | 0.180 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 186 | 0.170 |
Why?
|
| Cell Membrane | 2 | 2012 | 523 | 0.160 |
Why?
|
| Fas Ligand Protein | 2 | 2008 | 64 | 0.150 |
Why?
|
| Cell Movement | 2 | 2012 | 630 | 0.150 |
Why?
|
| Desipramine | 2 | 2006 | 47 | 0.140 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2019 | 381 | 0.140 |
Why?
|
| Drug Design | 2 | 2014 | 107 | 0.140 |
Why?
|
| Genes, Reporter | 2 | 2006 | 191 | 0.140 |
Why?
|
| Adaptation, Psychological | 1 | 2019 | 447 | 0.140 |
Why?
|
| Adenoviridae | 2 | 2006 | 295 | 0.140 |
Why?
|
| Blotting, Western | 3 | 2012 | 954 | 0.130 |
Why?
|
| Nitrobenzenes | 1 | 2014 | 13 | 0.130 |
Why?
|
| Prodrugs | 1 | 2014 | 54 | 0.120 |
Why?
|
| Karyopherins | 1 | 2013 | 11 | 0.120 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2013 | 55 | 0.120 |
Why?
|
| Taxoids | 1 | 2013 | 41 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 160 | 0.120 |
Why?
|
| Lysosomes | 3 | 2014 | 136 | 0.120 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 66 | 0.120 |
Why?
|
| Carbocyanines | 1 | 2012 | 13 | 0.110 |
Why?
|
| Cytochromes c | 1 | 2012 | 75 | 0.110 |
Why?
|
| Spectrum Analysis | 1 | 2012 | 81 | 0.110 |
Why?
|
| Coloring Agents | 1 | 2012 | 66 | 0.110 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 222 | 0.110 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2012 | 77 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2012 | 83 | 0.110 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2012 | 93 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2013 | 312 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2012 | 128 | 0.100 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 258 | 0.100 |
Why?
|
| Quality of Life | 1 | 2019 | 1515 | 0.100 |
Why?
|
| Amidohydrolases | 2 | 2007 | 60 | 0.100 |
Why?
|
| Chemokine CXCL13 | 1 | 2010 | 8 | 0.090 |
Why?
|
| Osteolysis | 1 | 2010 | 15 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 306 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 614 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2008 | 791 | 0.090 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 4843 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2008 | 434 | 0.090 |
Why?
|
| Caspases | 2 | 2007 | 194 | 0.090 |
Why?
|
| Prostate | 1 | 2009 | 116 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2008 | 140 | 0.080 |
Why?
|
| Chicken anemia virus | 1 | 2008 | 5 | 0.080 |
Why?
|
| Down-Regulation | 2 | 2007 | 447 | 0.080 |
Why?
|
| Sphingomyelin Phosphodiesterase | 2 | 2007 | 183 | 0.080 |
Why?
|
| Young Adult | 1 | 2019 | 5708 | 0.080 |
Why?
|
| Mouth Neoplasms | 1 | 2010 | 206 | 0.080 |
Why?
|
| Cell Survival | 2 | 2007 | 901 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 1753 | 0.080 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2008 | 200 | 0.070 |
Why?
|
| Genetic Vectors | 1 | 2008 | 311 | 0.070 |
Why?
|
| Phosphoserine | 1 | 2006 | 14 | 0.070 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2006 | 45 | 0.070 |
Why?
|
| Endosomes | 1 | 2006 | 45 | 0.070 |
Why?
|
| Cysteine Endopeptidases | 1 | 2006 | 39 | 0.070 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 236 | 0.070 |
Why?
|
| Female | 4 | 2019 | 38015 | 0.070 |
Why?
|
| Protein Transport | 1 | 2006 | 280 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 376 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 231 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2013 | 2688 | 0.060 |
Why?
|
| Gene Expression | 1 | 2006 | 770 | 0.060 |
Why?
|
| Disease Progression | 1 | 2007 | 1037 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2007 | 508 | 0.060 |
Why?
|
| Aged | 1 | 2019 | 14842 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2007 | 1173 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 710 | 0.050 |
Why?
|
| Middle Aged | 1 | 2019 | 21119 | 0.050 |
Why?
|
| Adult | 1 | 2019 | 21375 | 0.050 |
Why?
|
| HLA-DR4 Antigen | 1 | 2020 | 11 | 0.050 |
Why?
|
| Cathepsins | 1 | 2020 | 37 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2020 | 120 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2020 | 50 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 1293 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 122 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 226 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2019 | 139 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 329 | 0.040 |
Why?
|
| Combinatorial Chemistry Techniques | 2 | 2007 | 25 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2550 | 0.040 |
Why?
|
| Ceramidases | 2 | 2007 | 47 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2007 | 111 | 0.040 |
Why?
|
| Stereoisomerism | 2 | 2007 | 169 | 0.040 |
Why?
|
| Macrophages | 1 | 2020 | 647 | 0.040 |
Why?
|
| Molecular Structure | 2 | 2007 | 397 | 0.040 |
Why?
|
| Cell Line | 1 | 2020 | 1752 | 0.030 |
Why?
|
| Esters | 1 | 2014 | 22 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 80 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2014 | 237 | 0.030 |
Why?
|
| Protein Binding | 1 | 2014 | 1027 | 0.030 |
Why?
|
| Chemotaxis | 1 | 2010 | 38 | 0.020 |
Why?
|
| RANK Ligand | 1 | 2010 | 73 | 0.020 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2010 | 160 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2009 | 73 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1174 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 63 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2008 | 186 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2007 | 92 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2007 | 120 | 0.020 |
Why?
|
| Larynx | 1 | 2007 | 49 | 0.020 |
Why?
|
| Mitochondrial Membranes | 1 | 2007 | 45 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2007 | 200 | 0.020 |
Why?
|
| Pharynx | 1 | 2007 | 89 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2007 | 274 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 144 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 420 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2007 | 284 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 337 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1034 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2007 | 618 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2007 | 444 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1548 | 0.010 |
Why?
|